Literature DB >> 11025911

Successfully treating aggression in mentally ill prison inmates.

C F Lewis1.   

Abstract

The population of prison inmates in the United States is rapidly growing; in 1994 it was estimated that 1.7 million Americans were incarcerated. Changes in the complexion of the prison population highlight the need for successful mental health interventions for special populations. Specifically, increasing numbers of women, middle aged inmates, physically ill inmates, and inmates with severe mental illness have challenged an already taxed system. Many inmates have complex pathology in which substance abuse, psychosis, affective disorders, personality disorders and medical illnesses play overlapping roles. One of the most challenging aspects of care involves management of inmates who are aggressive to themselves or others. This article discusses the approach to managing inmates with aggressive behavior and complex mental health issues. Specific diagnoses are discussed as are the general approaches best used to assess new onset violent behavior in a mentally ill prison inmate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11025911     DOI: 10.1023/a:1004684223522

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  17 in total

1.  Midazolam for aggressivity and violence in three mentally retarded patients.

Authors:  W S Bond; L A Mandos; M B Kurtz
Journal:  Am J Psychiatry       Date:  1989-07       Impact factor: 18.112

2.  Lithium in the treatment of aggression in mentally handicapped patients. A double-blind trial.

Authors:  M Craft; I A Ismail; D Krishnamurti; J Mathews; A Regan; R V Seth; P M North
Journal:  Br J Psychiatry       Date:  1987-05       Impact factor: 9.319

3.  Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study.

Authors:  J Ratey; R Sovner; A Parks; K Rogentine
Journal:  J Clin Psychiatry       Date:  1991-04       Impact factor: 4.384

4.  Open prospective trial of fluoxetine for posttraumatic stress disorder.

Authors:  L M Nagy; C A Morgan; S M Southwick; D S Charney
Journal:  J Clin Psychopharmacol       Date:  1993-04       Impact factor: 3.153

5.  Sodium valproate in the treatment of behavioral disturbance in dementia.

Authors:  A M Mellow; C Solano-Lopez; S Davis
Journal:  J Geriatr Psychiatry Neurol       Date:  1993 Oct-Dec       Impact factor: 2.680

6.  Factors associated with a good response to lithium in aggressive mentally handicapped subjects.

Authors:  S P Tyrer; A Walsh; D E Edwards; T P Berney; D A Stephens
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1984       Impact factor: 5.067

7.  Behavioral effects of trazodone in Alzheimer's disease.

Authors:  F Lebert; F Pasquier; H Petit
Journal:  J Clin Psychiatry       Date:  1994-12       Impact factor: 4.384

8.  Prevalence of psychiatric disorders among incarcerated women. I. Pretrial jail detainees.

Authors:  L A Teplin; K M Abram; G M McClelland
Journal:  Arch Gen Psychiatry       Date:  1996-06

9.  The treatment of agitation during initial hospitalization after traumatic brain injury.

Authors:  M M Brooke; D R Patterson; K A Questad; D Cardenas; L Farrel-Roberts
Journal:  Arch Phys Med Rehabil       Date:  1992-10       Impact factor: 3.966

10.  Anger management and temper control: critical components of posttraumatic stress disorder and substance abuse treatment.

Authors:  P M Reilly; H W Clark; M S Shopshire; E W Lewis; D J Sorensen
Journal:  J Psychoactive Drugs       Date:  1994 Oct-Dec
View more
  2 in total

1.  Personality disorders in prison: aren't they all antisocial?

Authors:  Merrill Rotter; Bruce Way; Michael Steinbacher; Donald Sawyer; Hal Smith
Journal:  Psychiatr Q       Date:  2002

Review 2.  Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review.

Authors:  William Berger; Mauro V Mendlowicz; Carla Marques-Portella; Gustavo Kinrys; Leonardo F Fontenelle; Charles R Marmar; Ivan Figueira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-12-24       Impact factor: 5.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.